Quick answers
- What is Wixela Inhub?
- Wixela Inhub is a brand name of Fluticasone propionate and salmeterol, a prescription medicine. The FDA NDC Directory lists 4 Wixela Inhub products in 3 strengths and forms.
- Who makes Wixela Inhub?
- Mylan holds the FDA application for Wixela Inhub (ANDA208891, approved January 30, 2019). 1 other company (repackagers or distributors) also list Wixela Inhub products.
- Is there a generic or store brand of Wixela Inhub?
- Yes. The FDA NDC Directory lists 36 other products with the same active ingredients, strength and form as a Wixela Inhub product, 27 of them generic. Ask your pharmacist whether one is right for you.
- What do pharmacies pay for Wixela Inhub?
- CMS lists a National Average Drug Acquisition Cost (NADAC) for 3 Wixela Inhub strengths and forms (see the table below). That is what pharmacies pay to buy it, not what you pay: your price depends on your insurance and your pharmacy.
- Has Wixela Inhub been recalled?
- FDA enforcement reports list 1 recall of Wixela Inhub products; the newest started January 26, 2022. A recall usually concerns specific lots, not every product.
What Wixela Inhub is
Each Wixela Inhub product as listed in the FDA NDC Directory, by active ingredient, strength and form, with its official label. “Same medicine, other names” counts the other products with exactly the same active ingredients, strength and form (generic versions, store brands and other brands); inactive ingredients can differ.
Fluticasone propionate and salmeterol · prescription medicine
| Strength and form | Product names | Same medicine, other names | Label |
|---|---|---|---|
| fluticasone propionate 100 ug · salmeterol xinafoate 50 ug powder (respiratory (inhalation)) | Wixela Inhub | 13 products, 10 companies | DailyMed |
| fluticasone propionate 250 ug · salmeterol xinafoate 50 ug powder (respiratory (inhalation)) | Wixela Inhub | 14 products, 11 companies | DailyMed |
| fluticasone propionate 500 ug · salmeterol xinafoate 50 ug powder (respiratory (inhalation)) | Wixela Inhub | 9 products, 7 companies | DailyMed |
Its page lists every product and company, the FDA label’s uses and boxed warning, approvals, shortages and recalls: Fluticasone propionate and salmeterol →
FDA approval
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
| Application | Holder | First approved | Products |
|---|---|---|---|
| ANDA208891 | Mylan | January 30, 2019 | 4 |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| fluticasone propionate 100 ug · salmeterol xinafoate 50 ug powder | Generic: Wixela Inhub | $1.01 per unit Generic of the same strength and form: $1.01 per unit |
| fluticasone propionate 250 ug · salmeterol xinafoate 50 ug powder | Generic: Wixela Inhub | $1.21 per unit Generic of the same strength and form: $1.21 per unit |
| fluticasone propionate 500 ug · salmeterol xinafoate 50 ug powder | Generic: Wixela Inhub | $1.62 per unit Generic of the same strength and form: $1.62 per unit |
NADAC list of November 4, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list Wixela Inhub
The company named on the package (holder, repackager or distributor), as listed in the FDA NDC Directory, with its number of Wixela Inhub products.
- Mylan Pharmaceuticals Inc.3 products
- Bryant Ranch Prepack1 product
Recalls
From FDA enforcement reports, matched by the product’s NDC code or label. A recall usually covers specific lots: check the lot number on your package and ask your pharmacist. Do not stop a medicine on your own.
-
January 26, 2022 · Class II · Terminated · D-0202-2024
CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.
Inhub Wixela (fluticasone propionate and salmeterol inhalation powder, USP) 500/50MCG, 60 Doses of Inhalation Powder, Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, WV 26505. NDC: 0378-9320-32 — CARDINAL HEALTHCARE
Sources
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug labeling (SPL, openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- NADAC (National Average Drug Acquisition Cost) 2026 — Centers for Medicare & Medicaid Services (CMS), data.medicaid.gov, list of November 4, 2026, retrieved November 7, 2026
Which names get a brand page: a name the NDC Directory lists for a medicine, held by one company (the FDA application holder, or the company named on most of its products), that is not just a description, and that is not the only product of its medicine.